Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 3/20 | 0.80 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | OXTR | P30559 | 1/20 | 0.80 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.80 |
| ▸ | CD81 | P60033 | 1/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.65 |
| ▸ | RELA | Q04206 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.65 |
| ▸ | CES1 | P23141 | 3/20 | 0.65 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.65 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.65 |
| ▸ | PTPRC | P08575 | 2/20 | 0.65 |
| ▸ | PTPRF | P10586 | 2/20 | 0.65 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.65 |
| ▸ | ACP1 | P24666 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797167 | 0.90 | F3 (0.66) | F3SIRT5CYP3A4MAPK1OXTR | |
| SCHEMBL5797162 | 0.90 | F3 (0.66) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL18712289 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL18704435 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL17030511 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL4454760 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL741321 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL42864 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL21892162 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR | |
| Echinocystic Acid SCHEMBL13629642 | 0.89 | F3 (1.00) | F3SIRT5CYP3A4MAPK1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250089726-A1 | BOTANICAL BASED BIO-STIMULANT, BIO-ACARICIDAL COMPOSITIONS | KAY BEE BIO ORGANICS PVT LTD (IN) | 2025-03-20 | — | — | US | claimed |
| US-20240415129-A1 | BOTANICAL BASED BIO-INSECTICIDAL COMPOSITIONS FOR CONTROLLING PESTS AND IMPROVING THE PLANT PHYSIOLOGICAL PROCESS | KAY BEE BIO ORGANICS PVT LTD (IN) | 2024-12-19 | — | — | US | claimed |
| CN-107722146-A | Method for producing solid polyaluminoxane composition | 三井化学株式会社 | 2018-02-23 | — | — | CN | claimed |
| EP-1079824-B1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RES DEV FOUNDATION (US) | 2011-08-31 | — | — | EP | claimed |
| US-7780974-B2 | Avicin coated stents | RESEARCH DEVELOPMENT FOUNDATION (US) | 2010-08-24 | — | — | US | claimed |
| US-7670632-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2010-03-02 | — | — | US | claimed |
| EP-1079824-A4 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RES DEV FOUNDATION (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1355642-A4 | INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060148732-A1 | Inhibition of NF-kappaB by triterpene compositions | RESEARCH DEVELOPMENT FOUNDATION | 2006-07-06 | — | — | US | claimed |
| US-20060099236-A1 | Coated stents | RESEARCH DEVELOPMENT FOUNDATION (US) | 2006-05-11 | — | — | US | claimed |
| US-20030203049-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-10-30 | — | — | US | claimed |
| EP-1355642-A2 | INHIBITION OF NF-(k)B BY TRITERPENE COMPOSITIONS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030054052-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-03-20 | — | — | US | claimed |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-02-27 | — | — | US | claimed |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-02-13 | — | — | US | claimed |
| US-6444233-B1 | ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION | 2002-09-03 | — | — | US | claimed |
| WO-2002055016-A2 | INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| CN-1307473-A | Triterpene compositions and methods of their use | RES DEV FOUDATION (US) | 2001-08-08 | — | — | CN | claimed |
| EP-1079824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059578-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 1999-11-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203049-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | F3 1480/4885SIRT5 976/4885CYP3A4 2588/4885 |
| US-20060099236-A1 | Coated stents | CD68, TEK, AREG | F3 239/4885SIRT5 214/4885CYP3A4 3287/4885 |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | F3 1480/4885SIRT5 976/4885CYP3A4 2588/4885 |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | BAX, CASP3, ACACA | F3 812/4885SIRT5 1409/4885CYP3A4 1739/4885 |
| US-20060148732-A1 | Inhibition of NF-kappaB by triterpene compositions | NFKBIA, NFKB2, RELA | F3 533/4885SIRT5 2228/4885CYP3A4 3607/4885 |
| US-20030054052-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | F3 1480/4885SIRT5 976/4885CYP3A4 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.